Murat Inanç

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5447330/publications.pdf

Version: 2024-02-01

44042 18633 15,194 164 48 119 citations h-index g-index papers 165 165 165 13166 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern. Annals of the Rheumatic Diseases, 2022, 81, e110-e110.	0.5	1
2	Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 257-259.	0.7	2
3	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.5	42
4	Description of damage in different clusters of patients with antiphospholipid syndrome. Lupus, 2022, 31, 433-442.	0.8	5
5	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
6	A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis. Open Access Rheumatology: Research and Reviews, 2022, Volume 14, 39-42.	0.8	2
7	The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus, 2022, 31, 555-564.	0.8	1
8	Effect of Ground-Based Walk Training in Pulmonary Hypertension. American Journal of Cardiology, 2022, 174, 172-178.	0.7	1
9	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	2.2	17
10	A Case of Budd-Chiari Syndrome Associated With Antiphospholipid Syndrome Treated Successfully by Transjugular Intrahepatic Portosystemic Shunt. Clinical Medicine Insights: Case Reports, 2022, 15, 117954762211005.	0.3	0
11	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	1.5	60
12	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	1.5	13
13	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	1.5	22
14	Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. Journal of Thrombosis and Thrombolysis, 2021, 51, 466-474.	1.0	6
15	Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. Rheumatology International, 2021, 41, 439-448.	1.5	2
16	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	2.6	26
17	A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls. Rheumatology International, 2021, 41, 1667-1672.	1.5	2
18	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	0.9	14

#	Article	IF	Citations
19	The neurology of lupus. Journal of the Neurological Sciences, 2021, 424, 117419.	0.3	7
20	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3
21	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	2.9	7
22	Symptomatic osteonecrosis of the hip and knee in patients with systemic lupus erythematosus: Prevalence, pattern, and comparison of natural course. Lupus, 2021, 30, 1603-1608.	0.8	4
23	A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic. Turkish Journal of Medical Sciences, 2021, 51, 2243-2247.	0.4	3
24	Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab. Seminars in Arthritis and Rheumatism, 2021, 51, 1224-1229.	1.6	15
25	1704â€Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
26	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
27	Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center. Ulusal Romatoloji Dergisi, 2021, 13, 116-120.	0.0	0
28	Clinical characteristics of female patients with axial spondyloarthritis treated with tumor necrosis factor-alpha inhibitors and disease related outcomes after therapy. Ulusal Romatoloji Dergisi, 2021, 13, 100-106.	0.0	0
29	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	1.1	31
30	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	1.0	34
31	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
32	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23
33	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
34	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	3.0	27
35	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.5	40
36	Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review. Rheumatology International, 2020, 40, 1903-1910.	1.5	19

#	Article	IF	Citations
37	P69â€Risk factors for adverse pregnancy outcome in patients with SLE. , 2020, , .		0
38	P73â€The relationship between pregnancy, disease activity and adverse pregnancy outcomes in systemic lupus erythematosus. , 2020, , .		0
39	P9 Validation of the adjusted global antiphospholipid syndrome score and correlation with extra-criteria manifestations. , 2020, , .		0
40	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	1.5	9
41	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
42	Cardiovascular risk in antiphospholipid syndrome: A comparison of thrombotic and obstetric disease subsets. Ulusal Romatoloji Dergisi, 2020, 12, 83-87.	0.0	0
43	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
44	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	1.0	15
45	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
46	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	2.9	25
47	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	0.9	8
48	FRI0392â€EVIDENCE BASED RECOMMENDATIONS FOR THE MANAGEMENT OF ENTEROPATHIC ARTHRITIS: A RHEUMATOLOGY, GASTROENTEROLOGY COLLABORATIVE INITIATIVE. , 2019, , .		0
49	SATO184â€ASSOCIATION OF SERUM AND URINE LEVELS OF TWEAK, MCP-1 AND NGAL WITH DISEASE ACTIVITY SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	′ IN	O
50	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.5	12
51	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	2.9	55
52	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	0.9	37
53	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	1.5	55
54	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.5	50

#	Article	IF	CITATIONS
55	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53
56	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care and Research, 2018, 70, 98-103.	1.5	26
57	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	1.5	21
58	CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
59	Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events. Lupus, 2018, 27, 1509-1516.	0.8	13
60	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.5	268
61	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 2017, 26, 1051-1059.	0.8	52
62	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
63	Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey. Journal of Rheumatology, 2017, 44, 619-625.	1.0	41
64	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	1.6	1
65	Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 77-82.	0.4	7
66	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	2.9	40
67	Reply. Arthritis Care and Research, 2016, 68, 1053-1054.	1.5	1
68	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	1.1	51
69	Multicentric reticulohistiocytosis: Rheumatology perspective. Best Practice and Research in Clinical Rheumatology, 2016, 30, 250-260.	1.4	18
70	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	2.9	122
71	Capillaroscopic findings and vascular biomarkers in systemic sclerosis: Association of low CD40L levels with late scleroderma pattern. Microvascular Research, 2016, 108, 17-21.	1.1	13
72	Miscellaneous inflammatory musculoskeletal conditions: Always a diagnostic and therapeutic challenge. Best Practice and Research in Clinical Rheumatology, 2016, 30, 221.	1.4	0

#	Article	IF	Citations
73	Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities. Clinical Rheumatology, 2016, 35, 2495-2499.	1.0	7
74	Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus, 2016, 25, 177-184.	0.8	47
75	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	0.9	370
76	Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology, 2016, 3, 25-28.	1.3	14
77	Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey. Clinical and Experimental Rheumatology, 2016, 34, 1033-1037.	0.4	4
78	The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 110-114.	0.4	2
79	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> /i>/ <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	2.9	79
80	Assessment of Patients with Takayasu Arteritis in Routine Practice with Indian Takayasu Clinical Activity Score. Journal of Rheumatology, 2015, 42, 1443-1447.	1.0	19
81	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	2.9	98
82	Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care and Research, 2015, 67, 1237-1245.	1.5	88
83	The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome. Current Rheumatology Reports, 2015, 17, 14.	2.1	61
84	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.5	70
85	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.5	391
86	Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 2015, 24, 42-49.	0.8	106
87	The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S92-7.	0.4	8
88	The Relationship between P-Selectin Polymorphisms and Thrombosis in Antiphospholipid Syndrome: A Pilot Case-Control Study. Turkish Journal of Haematology, 2014, 31, 357-362.	0.2	9
89	Comparing femaleâ€based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population. International Journal of Rheumatic Diseases, 2014, 17, 653-657.	0.9	14
90	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.5	558

#	Article	IF	Citations
91	Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus from a Single Center. Journal of Rheumatology, 2014, 41, 1304-1310.	1.0	75
92	MEFV gene variations in patients with systemic lupus erythematosus. Modern Rheumatology, 2014, 24, 93-96.	0.9	8
93	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	2.6	143
94	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
95	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
96	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.5	1,705
97	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.5	78
98	Comparison of ultraviolet B-induced cutaneous inflammation and skin pathergy test in Behçet's disease. International Journal of Clinical Rheumatology, 2013, 8, 205-211.	0.3	0
99	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.5	143
100	Biologics use in sle in 23 centers $\hat{a} \in ``data from the international registry for biologics in SLE. Annals of the Rheumatic Diseases, 2012, 71, A9.1-A9.$	0.5	1
101	Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Research and Therapy, 2012, 14, R27.	1.6	60
102	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
103	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	1.5	49
104	Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatology International, 2012, 32, 79-83.	1.5	58
105	Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatology International, 2012, 32, 177-182.	1.5	68
106	Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. Clinical Rheumatology, 2012, 31, 325-328.	1.0	13
107	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Annals of the Rheumatic Diseases, 2011, 70, 1788-1792.	0.5	107
108	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Annals of the Rheumatic Diseases, 2011, 70, 54-59.	0.5	86

#	Article	IF	Citations
109	Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatology International, 2011, 31, 183-189.	1.5	50
110	A Prodrome of Acute Lymphoblastic Leukemia Mimicking Sacroiliitis. Electronic Journal of General Medicine, $2011, 8, \ldots$	0.3	1
111	Recurrent anterior uveitis in Henoch Schonlein's vasculitis. Rheumatology International, 2010, 30, 1377-1379.	1.5	6
112	The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. Journal of Thrombosis and Thrombolysis, 2010, 29, 303-309.	1.0	22
113	Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. Rheumatology, 2010, 49, 1889-1893.	0.9	97
114	Predictors of Damage and Survival in Patients with Wegener's Granulomatosis: Analysis of 50 Patients. Journal of Rheumatology, 2010, 37, 374-378.	1.0	31
115	Assessment Of Subclinical Cardiac Dysfunction In Diffuse Scleroderma Patients. Medical Journal of the Trakya University, 2009, , .	0.0	O
116	Rosai–Dorfman disease with factor XII deficiency. Clinical Rheumatology, 2009, 28, 733-736.	1.0	4
117	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2009, 29, 365-370.	1.5	8
118	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2008, 28, 959-964.	1.5	3
119	Faible fréquence d'HLA-B27 chez des patients atteints de spondylarthrite ankylosante en Turquie. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 433-437.	0.0	1
120	Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine, 2008, 75, 299-302.	0.8	50
121	P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2007, 66, 1378-1380.	0.5	21
122	Development of hairy cell leukemia in a patient with antiphospholipid syndrome. Lupus, 2007, 16, 286-288.	0.8	10
123	Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clinical Rheumatology, 2007, 26, 17-23.	1.0	76
124	Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clinical Rheumatology, 2007, 26, 1913-1915.	1.0	27
125	P-Selectin Glycoprotein Ligand-1 VNTR Polymorphisms in Systemic Sclerosis Blood, 2007, 110, 3914-3914.	0.6	0
126	Outcome measurements in scleroderma: results from a delphi exercise. Journal of Rheumatology, 2007, 34, 501-9.	1.0	45

#	Article	IF	Citations
127	Takayasu arteritis associated with systemic sclerosis. Modern Rheumatology, 2006, 16, 120-121.	0.9	8
128	Interleukin (IL)–12, IL-2, and IL-6 Gene Polymorphisms in Takayasu's Arteritis from Turkey. Human Immunology, 2006, 67, 735-740.	1,2	47
129	Accuracy of anti–ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta-analysis. Arthritis and Rheumatism, 2006, 54, 312-324.	6.7	201
130	Very early 'Rheumatoid' arthritis cohorts: limited by selection. Rheumatology, 2006, 46, 185-187.	0.9	8
131	Takayasu arteritis associated with systemic sclerosis. Modern Rheumatology, 2006, 16, 120-121.	0.9	5
132	Impaired endothelium-dependent flow-mediated dilation in BehÃSet's disease: more prominent endothelial dysfunction in patients with vascular involvement. International Journal of Clinical Practice, 2005, 59, 777-781.	0.8	38
133	Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet's disease: An open-label trial. Arthritis and Rheumatism, 2005, 52, 2478-2484.	6.7	289
134	Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatology International, 2005, 25, 211-214.	1.5	28
135	A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatology International, 2005, 25, 442-446.	1.5	41
136	Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. Rheumatology International, 2005, 26, 16-20.	1.5	6
137	Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clinical Rheumatology, 2005, 24, 673-676.	1.0	38
138	Assessment of Cardiac Structure and Left Atrial Appendage Functions in Primary Antiphospholipid Syndrome. Stroke, 2005, 36, 592-596.	1.0	51
139	Bilateral Acquired Brown Syndrome in Systemic Scleroderma. Journal of AAPOS, 2005, 9, 195-197.	0.2	8
140	Antiphospholipid Syndrome Presenting As Massive Pulmonary Embolism in a Patient With Sarcoidosis. Electronic Journal of General Medicine, 2005, 2, 173-176.	0.3	4
141	An Unusual Overdose of Leflunomide in a Patient with Rheumatoid Arthritis. Annals of Pharmacotherapy, 2004, 38, 1320-1321.	0.9	5
142	Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus, 2004, 13, 32-35.	0.8	15
143	Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. International Journal of Clinical Practice, 2004, 58, 1003-1007.	0.8	30
144	Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus, 2004, 13, 274-278.	0.8	90

#	Article	IF	Citations
145	Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia. European Journal of Internal Medicine, 2004, 15, 162-167.	1.0	25
146	The Prevalence and Clinical Significance of Inherited Thrombophilic Risk Factors in Patients with Antiphospholipid Syndrome Blood, 2004, 104, 4050-4050.	0.6	0
147	Fc receptor gamma subunit polymorphisms and systemic lupus erythematosus. Journal of King Abdulaziz University, Islamic Economics, 2004, 25, 1445-8.	0.5	3
148	Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener?s granulomatosis. Clinical Rheumatology, 2003, 22, 333-335.	1.0	19
149	A Patient with Classical Polyarteritis Nodosa Evolving into End Stage Renal Failure. Renal Failure, 2003, 25, 1037-1041.	0.8	5
150	Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome. Haematologia, 2002, 32, 73-77.	0.2	9
151	A weak association of HLA-B*2702 with Behçet's disease. Genes and Immunity, 2002, 3, 368-372.	2.2	61
152	Transforming growth factor-12 polymorphism and systemic lupus erythematosus. Journal of Rheumatology, 2002, 29, 1189-91.	1.0	3
153	Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood, 2001, 98, 1760-1764.	0.6	203
154	Amyopathic Dermatomyositis Associated with Cervical Cancer. Clinical Rheumatology, 2001, 20, 438-440.	1.0	14
155	European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Annals of the Rheumatic Diseases, 2001, 60, 592-598.	0.5	271
156	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Annals of the Rheumatic Diseases, 2001, 60, 585-591.	0.5	83
157	Familial aggregation of Behcet's disease in Turkey. Annals of the Rheumatic Diseases, 2000, 59, 622-625.	0.5	164
158	The Use of Two Different Health Assessment Questionnaires in Turkish Rheumatoid Arthritis Population and Assessment of the Associations with Disability. Clinical Rheumatology, 1999, 18, 33-37.	1.0	12
159	Predictors of lymphoma development in primary Sj \tilde{A} gren's syndrome. Seminars in Arthritis and Rheumatism, 1998, 28, 80-87.	1.6	124
160	Antibodies to \hat{l}^2 2-glycoprotein I in patients with systemic lupus erythematosus: Comment on the articles by Tsutsumi et al and Roubey et al. Arthritis and Rheumatism, 1997, 40, 1366-1366.	6.7	0
161	Primary antiphospholipid syndrome associated with mesenteric inflammatory veno-occlusive disease. Clinical Rheumatology, 1996, 15, 207-210.	1.0	34
162	Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus. Lupus, 1996, 5, 120-122.	0.8	17

Murat Inanç

#	Article	IF	CITATIONS
163	Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease: confirmed specificity but decreased sensitivity with sharp needles Annals of the Rheumatic Diseases, 1993, 52, 823-825.	0.5	100
164	Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and COVID-19. Journal of Clinical Rheumatology, O, Publish Ahead of Print, .	0.5	0